2015 American Transplant Congress
Influence of CYP3A5 and ABCB1 Genotypes on Pharmacokinetics of Immediate and Prolonged Release Tacrolimus Preparations
Background. Tacrolimus is available in two formulations, immediate-release, (Prograf®) and prolonged -release formulation of tacrolimus (Advagraf®). Tacrolimus has a narrow therapeutic index with wide variation…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Conversion from Immediate to Prolonged Release Tacrolimus Did Not Change Intra-Patient Variability in Renal Transplant Patients
Background. Tacrolimus has a narrow therapeutic index and is characterized by a large inter- and intra-patient variability (IPV). Variable blood tacrolimus concentrations have been shown…2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
1Univ of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…2015 American Transplant Congress
Alemtuzumab Induction Is Protective Against Acute Rejection in Kidney Recipients With Subtherapeutic Tacrolimus Concentrations
Transplant Surgery, University of North Carolina Hospitals, Chapel Hill, NC.
Purpose: To determine the effect of attaining early therapeutic tacrolimus (TAC) trough concentrations on biopsy-proven acute rejection (BPAR) within 12 months post-transplantation in adult kidney…2015 American Transplant Congress
Long-Term Follow-Up After Conversion from Twice-Daily Tacrolimus Formulation to Once-Daily Tacrolimus Formulation in Pediatric Kidney Transplantation
Surgery, Seoul National University College of Medicine, Seoul, Republic of Korea.
PurposeTacrolimus is one of the most frequently used immunosuppressants in pediatric kidney transplantation (KT) as in adult. In Pediatric kidney recipients, it is more important…2015 American Transplant Congress
Marked Suppression of Posttransplant Alloantibody Production and Primed B cell Function In Vivo by mTOR Inhibition Compared to Calcineurin Inhibition
Department of Surgery, CTC, The Ohio State University, Columbus, OH.
mTOR inhibitors [mTORi; Rapamycin, (Rapa)] and calcineurin inhibitors [CNi; Tacrolimus (Tac)] are immunosuppressives commonly used to suppress rejection of transplants. Despite widespread use following transplantation…2015 American Transplant Congress
A Prospective and Randomized Study of Conversion from Tacrolimus to Cyclosporine A to Improve Glucose Metabolism in Patients With New-Onset Diabetes Mellitus After Renal Transplantation
Background: The present prospective and randomized study was designed to assess whether conversion from tacrolimus (Tac) to cyclosporine A (CsA) can reverse posttransplantation diabetes mellitus…2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…2015 American Transplant Congress
Tacrolimus Trough Concentrations Increase in Intestinal Transplant Recipients During Episodes of Acute Cellular Rejection
Introduction: Acute cellular rejection (ACR) in small bowel transplant recipients is expected to increase intestinal permeability and to reduce intestinal CYP3A/p-glycoprotein activity. These changes may…
American Transplant Congress abstracts